A judge has ruled that hospitals and insurers will now be required to disclose pricing for common tests and procedures in order to provide transparency for patients. The rule will go into effect in January. However, the American Hospital Association is planning to appeal the decision which could affect whether the rule comes into play. (AP News)
Gilead’s remdesivir could be priced at $5,080 per treatment, according to a U.S. drug pricing group. Originally, the recommendation for pricing was $4,500. The Institute for Clinical and Economic Review has suggested a range of $2,520 to $2,800. (Reuters)
States may not need to shut down again, but they should consider going back a phase or two, according to Dr. Anthony Fauci. In states where coronavirus is spiking, like Texas, Arizona and Florida, reopening phases could be paused or rolled back to combat the spread. (CNBC)
MM&M has launched an initiative advocating for equal outcomes in healthcare. #CreateHealthEquity is a call for the industry to create campaigns that convince the world that access to quality healthcare is a fundamental human right. (MM&M)
Bayer is settling its Roundup lawsuits for $10.9 billion. The U.S. lawsuits, amounting to more than 125,000 filed and unfiled claims, argue that the weedkiller caused cancer. (Reuters)
